| Identification | Back Directory | [Name]
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) | [CAS]
1242169-24-9 | [Synonyms]
PC407ws
PC407-ws
PC407 ws
Butanoic acid, 4-[[[4-[5-(2-naphthalenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]-4-oxo-, sodium salt (1:2) | [Molecular Formula]
C24H19F3N3NaO5S | [MOL File]
1242169-24-9.mol | [Molecular Weight]
541.48 |
| Hazard Information | Back Directory | [Description]
PC407-ws is a water-soluble novel potential COX-2 inhibitor. | [Uses]
COX-2-IN-50 is a water-soluble COX-2 inhibitor with significant analgesic activity. The solubility of COX-2-IN-50 in water reaches 20.3 mg/mL, far exceeding the 1.6 μg/mL of its precursor compound PC407. COX-2-IN-50 demonstrates good biocompatibility and is suitable for the development of injectable dosage forms. COX-2-IN-50 has proven its analgesic effect in vivo and shows potential application value[1]. | [References]
[1] Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation |
|
|